Satyendra Suryawanshi
About Satyendra Suryawanshi
Satyendra Suryawanshi is the Director at Bristol-Myers Squibb, leading Clinical Pharmacology & Pharmacometrics for oncology asset development.
Title
Satyendra Suryawanshi holds the title of Director at Bristol-Myers Squibb. His role emphasizes leadership in the Clinical Pharmacology & Pharmacometrics field, particularly for oncology therapeutic areas. His work spans both early and late-stage asset development.
Company
Satyendra Suryawanshi is currently employed at Bristol-Myers Squibb, a globally recognized biopharmaceutical company. Bristol-Myers Squibb specializes in the discovery, development, and delivery of innovative medicines for patients with serious diseases. Satyendra joined the company in April 2019 and has held a pivotal role in advancing oncology treatments.
Clinical Pharmacology and Pharmacometrics Leadership
As Director at Bristol-Myers Squibb, Satyendra Suryawanshi leads the Clinical Pharmacology & Pharmacometrics efforts. His responsibilities include overseeing the development of early and late-stage assets, specifically within the Oncology Therapeutic Area. His work is critical in guiding the strategic direction and implementation of pharmacometric modeling and clinical pharmacology plans to optimize oncology treatments.
Background in Oncology Treatment Development
Satyendra Suryawanshi specializes in the development of oncology treatments. His expertise encompasses a wide range of activities, from initial clinical pharmacology studies to later-stage pharmacometric modeling. His strategic leadership in this area has contributed to advancing therapeutic options for cancer patients.